Ratutrelvir (COVID): Potential best-in-class therapy to minimize the risk of viral rebound and Long COVID Exhibit 99.1 Traws Pharma Reports Third Quarter 2025 Results and Business Highlights Progressing Phase 2 studies for ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long COVID with expected top line data by year end Significant intellectual property and other assets acquired Significant cost reductions quarter over quarter NEWTOWN, PA, November 13, 2025 (GLOBE NEWS ...